These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1618598)

  • 1. The macroscopic and microscopic pharmacology of monoclonal antibodies.
    Weinstein JN; van Osdol W
    Int J Immunopharmacol; 1992 Apr; 14(3):457-63. PubMed ID: 1618598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
    Fujimori K; Covell DG; Fletcher JE; Weinstein JN
    J Nucl Med; 1990 Jul; 31(7):1191-8. PubMed ID: 2362198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".
    van Osdol W; Fujimori K; Weinstein JN
    Cancer Res; 1991 Sep; 51(18):4776-84. PubMed ID: 1893370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of monoclonal antibody distribution and radiation dose in tumors: a modeling analysis.
    Fujimori K
    Hokkaido Igaku Zasshi; 1991 May; 66(3):369-84. PubMed ID: 1885162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.
    Sung C; Shockley TR; Morrison PF; Dvorak HF; Yarmush ML; Dedrick RL
    Cancer Res; 1992 Jan; 52(2):377-84. PubMed ID: 1728409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism.
    Baxter LT; Jain RK
    Microvasc Res; 1991 Jan; 41(1):5-23. PubMed ID: 2051954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.
    Fujimori K; Covell DG; Fletcher JE; Weinstein JN
    Cancer Res; 1989 Oct; 49(20):5656-63. PubMed ID: 2790783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.
    Juweid M; Neumann R; Paik C; Perez-Bacete MJ; Sato J; van Osdol W; Weinstein JN
    Cancer Res; 1992 Oct; 52(19):5144-53. PubMed ID: 1327501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity and avidity in antibody-based tumor targeting.
    Rudnick SI; Adams GP
    Cancer Biother Radiopharm; 2009 Apr; 24(2):155-61. PubMed ID: 19409036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier".
    Weinstein JN; van Osdol W
    Cancer Res; 1992 May; 52(9 Suppl):2747s-2751s. PubMed ID: 1563006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-antigen-binding bispecific antibodies for cancer treatment.
    Weidle UH; Kontermann RE; Brinkmann U
    Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution.
    Fujimori K; Fisher DR; Weinstein JN
    Cancer Res; 1991 Sep; 51(18):4821-7. PubMed ID: 1893374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure.
    Jain RK; Baxter LT
    Cancer Res; 1988 Dec; 48(24 Pt 1):7022-32. PubMed ID: 3191477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays.
    Kaufman EN; Jain RK
    Cancer Res; 1992 Aug; 52(15):4157-67. PubMed ID: 1638531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human-human monoclonal antibody directed against tumor surface antigen in the treatment of human malignancy. A pilot study.
    Alonso K
    Am J Clin Oncol; 1991 Dec; 14(6):463-71. PubMed ID: 1957834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of five monoclonal anti-CEA antibodies with different epitope specificities to various carcinoma tissues.
    Wagener C; Petzold P; Köhler W; Totović V
    Int J Cancer; 1984 Apr; 33(4):469-75. PubMed ID: 6200447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of solid tumors: from fairytale to reality.
    Adams GP; Weiner LM
    Cancer Biother Radiopharm; 2001 Feb; 16(1):9-11. PubMed ID: 11279802
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors.
    Sharifi J; Khawli LA; Hu P; King S; Epstein AL
    Hybrid Hybridomics; 2001; 20(5-6):305-12. PubMed ID: 11839248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
    Jain RK
    Cancer Res; 1990 Feb; 50(3 Suppl):814s-819s. PubMed ID: 2404582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.
    Graff CP; Wittrup KD
    Cancer Res; 2003 Mar; 63(6):1288-96. PubMed ID: 12649189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.